Evaluation of the Role of the Noradrenergic System in Pain Perception in Parkinson's Disease (DOULOX)

Toulouse University Hospital

Status and phase: Completed; Phase 3

Conditions: Parkinson's Disease

Treatments: Drug: injection of placebo of L-Dopa; Drug: L-Dopa; Drug: injection of apomorphine; Drug: duloxetine; Drug: placebo of duloxetine; Drug: injection of placebo of apomorphine

Study type: Interventional

Funder types: Other

Identifiers

NCT01504178

09 303 03

Details and patient eligibility

About

Patients suffering from Parkinson's disease (PD) frequently experienced painful sensations that could be, in part, due to a central modification of nociception mechanisms. Previous studies have shown that pain perception was altered in Parkinson's disease (subjective and objective pain thresholds and pain-induced cerebral activity) and that administration of L-Dopa normalized this alteration. In the central nervous system, L-Dopa is converted in dopamine and in norepinephrine. Apomorphine (a dopamine agonist) has no effect on pain threshold and pain-induced cerebral activity. Therefore the noradrenergic system could be involved in pain alteration in PD.

To assess the role of noradrenergic system in pain in patients with PD, we chose duloxetine (norepinephrine and serotonin reuptake inhibitor)because a recent study had shown that duloxetine allowed an improvement of pain clinical scores (pain questionnaires) in patients with PD.

36 patients will be enrolled in this study. We supposed that a chronic intake of duloxetine increase the pain perception level compare to the placebo. This increase would be the same than those observed with L-Dopa.

Enrollment: 28 patients

Sex: All

Ages: 30 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with clinical diagnosis of Parkinson's disease according to the criteria of the UKPDSBB
• Parkinson's disease patients with a score ≤ 3 on the Hoehn and Yahr scale
• Patients treated with dopaminergic antiparkinsonian drugs (L-Dopa, dopamine agonists, ICOMT...)
• Patients affiliated to a social protection program
• Women with efficacy contraception

Exclusion criteria

• Patients suffering from another pathology causing chronic pain (rheumatic disease, traumatic or orthopedic pathologies...)
• Parkinson's disease patients with a score > 3 on the Hoehn and Yahr scale
• Depressed patients (MADRS score < 16)
• Patients suffering from a cancer
• Patients under tutelage, curatella or law protection
• Patients with a complete contraindication against apomorphine injections or duloxetine administration (selective serotonin reuptake inhibitor and monoamine oxydase inhibitors)
• Patients without any control of their arterial hypertension
• Patients with a neuroleptic treatment
• Pregnant women

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

28 participants in 3 patient groups, including a placebo group

duloxetine

Experimental group

Description:

The first group (12 patients) will receive, after 28 days of duloxetine treatment, one duloxetine dose, an injection of apomorphine and a placebo of L-Dopa.

Treatment:

Drug: duloxetine

Drug: injection of apomorphine

Drug: injection of placebo of L-Dopa

positive control (L-Dopa)

Placebo Comparator group

Description:

The second group (12 patients) will receive, after 28 days of placebo treatment, one placebo dose of duloxetine, an injection of apomorphine and injection of placebo of L-Dopa.

Treatment:

Drug: injection of apomorphine

Drug: injection of placebo of L-Dopa

Drug: placebo of duloxetine

negative control

Placebo Comparator group

Description:

The third group will receive, after 28 days of placebo treatment, one placebo of duloxetine, an injection of placebo of apomorphine and a dose of L-Dopa.

Treatment:

Drug: injection of placebo of apomorphine

Drug: placebo of duloxetine

Drug: L-Dopa